A total of 29 new blockbuster-in-waiting drugs entered the late-stage pipeline in 2024, a jump from the previous year’s 19.

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

Teacher Retirement System of Texas lifted its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report ...

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...

In the assessment of 12-month price targets, analysts unveil insights for Lexicon Pharmaceuticals, presenting an average ...

Raymond James Financial Inc. acquired a new position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free ...

Projected return on investment in pharma research and development (R&D) in 2024 has risen to 5.9%, continuing the upward ...

JP Morgan sees strong growth for Ascentage Pharma, citing its late-stage cancer drugs. The biotech's 2024 sales surged 342% ...

Partex's platform will provide comprehensive analyses, including target identification, indication expansion, and molecular profiling, ultimately accelerating the process of bringing innovative ...

I aim to bring my diverse experience across multiple continents and network encompassing the pharmaceutical, asset management and investment banking industries to drive Alvotech's goal of ...